series-a
Stage
1
Investors
About
Tenboron develops novel boron carriers for Boron Neutron Capture Therapy (BNCT), a targeted cancer radiotherapy that delivers boron-10 to cancer cells to selectively destroy them while sparing healthy tissue. Their lead product TB0010 is advancing towards a phase 1b clinical trial for recurrent head and neck carcinomas.
Explore Tenboron's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.